Skip to main navigation
Disability accessibility tool
  • Contact Us
Neurocrine Biosciences logo
  • Your Health
    • Diseases & Conditions
    • Approved Medicines
    • TD Awareness
    • Investigational Therapies
  • Our Science
    • Approved Medicines
    • Pipeline
    • Clinical Studies
  • Our Company
    • About Us
    • Leadership
    • News & Media
    • Our Responsibility
    • DE&I
    • Grants & Sponsorships
  • Investors
    • Investor Overview
    • Stock Information
    • Financial Communications
    • Governance
    • Sustainability
    • Business Development
    • Webcasts & Presentations
  • Careers
    • Meet Our People
    • Work with Us
    • Explore Our Benefits
  • Your Health
    • Diseases & Conditions
    • Approved Medicines
    • TD Awareness
    • Investigational Therapies
  • Our Science
    • Approved Medicines
    • Pipeline
    • Clinical Studies
  • Our Company
    • About Us
    • Leadership
    • News & Media
    • Our Responsibility
    • DE&I
    • Grants & Sponsorships
  • Investors
    • Investor Overview
    • Stock Information
    • Financial Communications
    • Governance
    • Sustainability
    • Business Development
    • Webcasts & Presentations
  • Careers
    • Meet Our People
    • Work with Us
    • Explore Our Benefits
+
  • Investor Overview
  • Stock Information
    • Stock Quote
    • Shareholder Contacts
    • Analyst Coverage
  • Financial Communications
    • SEC Filings
    • Annual Meeting
    • Annual Reports
  • News Releases
  • Corporate Governance
  • Sustainability
  • Business Development
  • Webcasts & Presentations

Investor Overview

Latest News Releases

View All
3/21/23
Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
Read More
3/9/23
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
Read More
3/9/23
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference
Read More

2021 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)
  • Change
  • Volume
  • 52 Week High
  • 52 Week Low

03/25/23 12:42 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date Form Description Filing Group View
02/24/23 8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML
0000914475-23-000016.pdf
0000914475-23-000016.rtf
0000914475-23-000016.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
02/24/23 SC 13D/A

An amendment to a SC 13D filing

Other
View HTML
0001193125-23-047416.pdf
0001193125-23-047416.rtf
0001193125-23-047416.xls
02/24/23 4

Statement of changes in beneficial ownership of securities

3,4,5
View HTML
0000899243-23-006093.pdf
0000899243-23-006093.rtf
0000899243-23-006093.xls

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report

Email Alerts

Sign up to automatically receive Neurocrine Biosciences financial information by email

Sign Up Now

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts

 
Neurocrine logo
  • Diseases & Conditions
  • News & Media
  • Approved Medicines
  • Careers
  • Investigational Therapies
  • Leadership
  • Pipeline
  • Investors
  • Clinical Studies
  • Our Responsibility
Follow Us
Facebook logo
Linkedin logo
Twitter logo
©2022 Neurocrine Biosciences, Inc. All rights reserved.
 
  • Contact
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Accessibility
  • Sitemap